Wednesday, September 27, 2023
No Result
View All Result
  • বাংলা সংস্করণ
Shomporko
Advertisement
  • Home
  • News
    • Daily News
    • Feature
    • Sports
  • CANADA
    • Canada Daily
    • Community News
    • Canada Politics
    • Canada Economy
    • Canada Health
  • Global
  • Bangladesh
  • Interview
  • Article
    • Analytical
  • LITERATURE
    • Story
    • Poem
  • Opinion
    • Columnists
  • More
    • Food & Beverage
    • HISTORY
    • Kids Page
    • Travel
    • HOME DECOR
    • Video
    • Social Media
    • Festival
  • Home
  • News
    • Daily News
    • Feature
    • Sports
  • CANADA
    • Canada Daily
    • Community News
    • Canada Politics
    • Canada Economy
    • Canada Health
  • Global
  • Bangladesh
  • Interview
  • Article
    • Analytical
  • LITERATURE
    • Story
    • Poem
  • Opinion
    • Columnists
  • More
    • Food & Beverage
    • HISTORY
    • Kids Page
    • Travel
    • HOME DECOR
    • Video
    • Social Media
    • Festival
No Result
View All Result
Shomporko
No Result
View All Result
Home Canada Daily

The Canadian company says its COVID-19 vaccine spurred ‘promising antibody response’ in Phase 1 of trials

by Shomporko
November 11, 2020
in Canada Daily
0
The Canadian company says its COVID-19 vaccine spurred ‘promising antibody response’ in Phase 1 of trials
0
SHARES
26
VIEWS
Share on FacebookShare on Twitter

The Canadian company behind a new plant-derived COVID-19 vaccine candidate has released the results of their Phase 1 clinical trials, saying two doses of their adjuvanted vaccine spurred a significant antibody response in 100 per cent of the trial subjects.

“They’re even better than we had hoped,” Nathalie Landry, executive vice president of scientific and medical affairs at Medicago, said of the results.

“When we talk about neutralizing antibody responses, we say it’s quite remarkable, especially when we compare with a subject that recovered from the disease.”

Those who received the Medicago adjuvanted vaccine in the Phase 1 trial actually had higher antibody levels than the levels found in those who had contracted COVID-19,

Medicago, a company based in Quebec, launched its first human trials in July.

In Phase 1, they looked at around 180 healthy subjects between the ages of 18 and 55. Participants were given either the vaccine on its own or the vaccine with one of two adjuvants mixed in GlaxoSmithKline (GSK)’s pandemic adjuvant or Dynavax’s CpG 1018.

An adjuvant is a substance that is added to vaccines in order to boost the effects and enable a higher immune response. They can be made from a variety of materials, including plants, aluminum and squalene oil, derived largely from sharks. Researchers wanted to measure what difference adding each adjuvant would make for the immune response.

They found that the vaccine candidate on its own did produce antibodies in the subjects, but demanded a much higher dosage level in order to get proper results.

It was the adjuvanted vaccines that really had an effect.

After two doses of adjuvanted vaccine — no matter which adjuvant was used — the antibody response rose significantly. However, subjects developed anti-spike IgG antibodies after a single dose of the vaccine when mixed with the GSK adjuvant, according to the press release.

“[GSK’s was] the adjuvant that provided us with the best immune response at [a] very low dose,” Landry said.

She explained that although they tested three doses at 3.75, 7.5 and 15 micrograms, the antibody response did not increase as the dosage went up.

“We only need 3.75 micrograms to get to a very significant level of antibody and cellular immune responses,” she said.

Being able to spur an immune response at a lower dose means they would be able to manufacture more of the vaccine — if it clears the rest of the phases.

In October, the company announced that they had reached an agreement with the federal government to supply Canada with up to 76 million doses of their vaccine, subject to approval from Health Canada.

The success of the GSK adjuvant means that moving forward, Medicago will be using only their vaccine candidate mixed with GSK’s pandemic adjuvant in further trials.

This phase also proved the safety of the vaccine candidate to proceed to further trials, as no subjects had any severe adverse side-effects, only mild and short-lived side-effects, according to the release.

Photo credit: THE CANADIAN PRESS/Graham Hughes

News source: CTV News

Previous Post

Bengali nation could not keep Bangabandhu’s trust: PM Hasina

Next Post

Opioid-related deaths spike in Ontario during the pandemic, a new report finds

Shomporko

Related Posts

NORAD says storm won’t slow Santa’s travels
Canada Daily

NORAD says storm won’t slow Santa’s travels

December 25, 2022
Catholics return to GTA churches for full-capacity Christmas masses
Canada Daily

Catholics return to GTA churches for full-capacity Christmas masses

December 25, 2022
List of GTA school cancellations during holiday winter storm
Canada Daily

List of GTA school cancellations during holiday winter storm

December 23, 2022
Toronto could still be digging out from major winter storm on Christmas Day, city officials warn
Canada Daily

Toronto could still be digging out from major winter storm on Christmas Day, city officials warn

December 23, 2022
Popular arena in the Junction to close unexpectedly for months due to emergency roof repairs
Canada Daily

Popular arena in the Junction to close unexpectedly for months due to emergency roof repairs

December 22, 2022
Woman, child seriously injured after being hit by vehicle in Cedarvale
Canada Daily

Woman, child seriously injured after being hit by vehicle in Cedarvale

December 22, 2022
Next Post
Opioid-related deaths spike in Ontario during the pandemic, a new report finds

Opioid-related deaths spike in Ontario during the pandemic, a new report finds

Logo

Disclaimer:

The editorial team is not responsible for the content of the writing.

Publisher and Editor
Sonia Hoque

General Manager

Rewrite-Man

Reporter

Graphics
Mozammel Sarkar

Address:

Shomporko Magazine

59 Byng ave
Scarborough,
Ontario
M1L3N8

Phone :647-686-5432

 

Email: 
shomporko.magazine@gmail.com
2537765 Ontario Ltd

© 2020 Shomporko – Magazine Develop by RMITtech

No Result
View All Result
  • Home
  • NEWS
    • Daily News
    • Feature
    • Global
    • Politics
    • Sports
  • CANADA
    • Canada Daily
    • Community News
    • Canada Politics
    • Canada Economy
    • Canada Immigration
    • Canada Education
    • Canada Health
    • Canada Opinion
  • GLOBAL
  • INTERVIEW
  • ARTICLE
    • Analytical
  • LITERATURE
    • Story
    • Poem
  • OPINION
    • Opinion
    • Columnists
    • Legal Advice
  • ARTS
    • Home Decor
    • Sports
  • LIVING
    • Health
    • Food
    • Travel
    • HISTORY
    • Kids Page
  • MORE
    • Video
    • Social Media
    • Festival
  • বাংলা সংস্করণ

© 2019 Shomporko - Magazine Develop by RMITtech.

Translate »